Q1 Revenue Drops 11.4%, Net Loss Widens Amid Going Concern & Major Dilution

summarizeSummary

CV Sciences reported an 11.4% revenue drop and a wider net loss in Q1 2026, reiterated its going concern warning, and detailed significant dilution from convertible notes, while facing a major regulatory threat and a $13 million legal dispute.

check_boxKey Events

• Q1 2026 Financial Performance

  Net product sales decreased by 11.4% to $3.195 million from $3.606 million in Q1 2025. The net loss widened significantly to $0.643 million from $0.109 million in the prior year period. Gross margin improved to 48.9% from 46.0%, and cash flow from operations turned positive at $0.1 million, compared to a negative $0.081 million in Q1 2025.

• Going Concern Warning Reiterated

  The company continues to raise substantial doubt about its ability to continue as a going concern, citing negative cash flows from operations in prior years and an accumulated deficit of $88.6 million as of March 31, 2026.

• Significant Dilution from Convertible Notes

  The company amended existing promissory notes in March and April 2026, setting a fixed conversion price of $0.03 per share. During Q1 2026, 9.19 million shares were issued at a weighted average conversion price of $0.06 per share. Subsequent to Q1, an additional 10.52 million shares were converted at $0.04 per share, and two new 'Third Notes' totaling $0.256 million were issued due to conversion shortfalls.

• Major Regulatory Headwind

  New federal legislation, effective November 13, 2026, will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container. The company is evaluating the potential material adverse impact on its product portfolio and future operating results.

auto_awesomeAnalysis

CV Sciences, a micro-cap company, reported a significant revenue decline and a wider net loss for Q1 2026, reinforcing its ongoing 'going concern' warning. The company continues to rely on highly dilutive convertible notes, with recent conversions occurring at or below the current stock price, leading to a substantial increase in outstanding shares. A new federal regulation effective November 2026 poses a material adverse risk to its core hemp-derived product business. Additionally, the company is engaged in a high-stakes arbitration against former legal counsel for alleged damages of $13 million, an amount significantly exceeding its current market capitalization.